In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration

Neoplasia

Volumn 9, Issue 12, 2007, Pages 1030-1037

  Loberg, Robert D ^a,b   McGregory, Natalie ^b   Ying, Chi ^b   Sargent, Erin ^b   Pienta, Kenneth J ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Bcl 2; BH3 domain; Hormone refractory; Orchiectomy

Indexed keywords

ANDROGEN; CASPASE 3; CASPASE 9; GOSSYPOL ACETIC ACID; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CASTRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INDUCTION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; UPREGULATION;

EID: 37149035009     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07778     Document Type: Article

References (20)

1. Shi Y, Chatterjee SJ, Brands FH, Shi SR, Pootrakul L, Taylor CR, Datar R, and Cote RJ (2006). Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations. BJU Int 97, 170-178.
2. Pegoraro L, Palumbo A, Erikson J, Falda M, Giovanazzo B, Emanuel BS, Rovera G, Nowell PC, and Croce CM (1984). A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. Proc Natl Acad Sci USA 81, 7166-7170.
3. Gross A, McDonnell JM, and Korsmeyer SJ (1999). BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13, 1899-1911.
4. Letai A (2003). BH3 domains as BCL-2 inhibitors: prototype cancer therapeutics. Expert Opin Biol Ther 3, 293-304.
5. Oliver CL, Bauer JA, Wolter KG, Ubell ML, Narayan A, O'Connell KM, Fisher SG, Wang S, Wu X, Ji M, et al. (2004). In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res 10, 7757-7763.
6. Mohammad RM, Wang S, Aboukameel A, Chen B, Wu X, Chen J, and Al-Katib A (2005). Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther 4, 13-21.
7. Jiang J, Sugimoto Y, Liu S, Chang HL, Park KY, Kulp SK, and Lin YC (2004). The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor beta1 (TGFβ1) signal transduction pathway. Anticancer Res 24, 91-100.
8. Wolter KG, Wang SJ, Henson BS, Wang S, Griffith KA, Kumar B, Chen J, Carey TE, Bradford CR, and D'Silva NJ (2006). (-)-Gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia 8, 163-172.
9. Van Poznak C, Seidman AD, Reidenberg MM, Moasser MM, Sklarin N, Van Zee K, Borgen P, Gollub M, Bacotti D, Yao TJ, et al. (2001). Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res Treat 66, 239-248.
10. Loberg RD, St John LN, Day LL, Neeley CK, and Pienta KJ (2006). Development of the VCaP androgen-independent model of prostate cancer. Urol Oncol 24, 161-168.
11. L, (-)-gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line. Pancreas 31, 317-324.
12. L with nonpeptidic small-molecule antagonists. Semin Oncol 30, 133-142.
13. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, et al. (2004). Androgenin-dependent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64, 9209-9216.
14. Nelson WG, De Marzo AM, and Isaacs WB (2003). Prostate cancer. N Engl J Med 349, 366-381.
15. Debes JD and Tindall DJ (2004). Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351, 1488-1490.
16. Feldman BJ and Feldman D (2001). The development of androgen-independent prostate cancer. Nat Rev Cancer 1, 34-45.
17. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, and Sawyers CL (2004). Molecular determinants of resistance to antiandrogen therapy. Nat Med 10, 33-39.
18. Grossmann ME, Huang H, and Tindall DJ (2001). Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93, 1687-1697.
19. Navarro D, Luzardo OP, Fernandez L, Chesa N, and Diaz-Chico BN (2002). Transition to androgen-independence in prostate cancer. J Steroid Biochem Mol Biol 81, 191-201.
20. Lui G, Wilding G, and Somer B (2007). An open-label, multicenter, phase II study of single-agent AT-101 in men with hormone refractory prostate cancer (HRPC) and rising prostate-specific antigen (PSA) levels who have not received prior chemotherapy. Abstract No. 258 Proceedings of the Prostate Cancer Symposium.